October 25, 2014 11:59 PM ET

Diversified Financial Services

Company Overview of Fondation Santé

Executive Profile

Spyros Artavanis-Tsakonas Ph.D.

Chief Scientific Officer and Senior Vice President, Biogen Idec Inc.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 3 different industries.

See Board Relationships
67--

Background

Prof. Spyros Artavanis-Tsakonas, Ph.D. has been the Chief Scientific Officer and Senior Vice President of Biogen Idec Inc. since May 2013. Prof. Artavanis-Tsakonas is the Scientific Co-Founder of Exelixis Pharmaceuticals, Inc., Cellzome, a GSK company, and Anadys Pharmaceuticals, Inc. He serves as the President of Fondation Santé. Prof. Artavanis-Tsakonas served as Interim Chief Scientific Officer while on sabbatical from Harvard Medical School. Prof. Artavanis-Tsakonas ...

Corporate Headquarters

54 Afaias Street
Athens, -- 15452

Greece

Phone: 30 21 06 71 036
Fax: --

Board Members Memberships

President and Director
Chairman

Education

PhD
University of Cambridge
MS
Eidgenössische Technische Hochschule Zürich
Post-Doctoral Training
The Leland Stanford Junior University
Post-Doctoral Training
Universität Basel

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Lamberto Andreotti Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee
Bristol-Myers Squibb Company
$1.7M
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
$1.3M
Lars Rebien Sørensen Chief Executive Officer and Member of Executive Management
Novo Nordisk A/S
$15.2M
Flemming Ornskov M.D., MBA, MPHManaging Director, Chief Executive Officer and Director
Shire plc
$2.7M
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Fondation Santé, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.